[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [2] Honkoop P,De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs,2003,12:683-688. [3] Leung N,Peng CY,Hann HW,et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B:a randomized international study of entecavir versus aderfovir. Hepatology,2009,49:72-79. [4] 达瓦桑姆,达瓦,姜倩,等. 西藏自治区2202名藏族人群乙型肝炎病毒感染影响因素研究.中华流行病学杂志,2011,32(4):427-428. [5] 中华医学会肝病学分会和传染病与寄生虫病学会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8(6):324-329. [6] 郭开瑜. 西藏地区藏族中乙型肝炎流行情况调查.临床肝胆病杂志,1988,10(3),17. [7] Tenny DJ,Rose RE,Baldick CJ,et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-navive patients is rare through 5 years of theraphy.Hepatology,2009,49:1503-1514. [8] Marzano A,Marengo A,Marietti M,et al. Lactic acidosis during entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liver Dis,2011,43(12):1027-1028. |